Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 4Active not recruiting 4Completed 2Unknown 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 36Gastrointestinal 18CNS 7Thoracic 6Breast 6Endocrine 5Tumor-Agnostic 4Head & Neck 4Gynecologic 4Sarcoma 3Dermatologic 3Plasma cell 2Other solid neoplasm 2NET 2Other hematologic neoplasm 1

Conditions

Neuroendocrine Tumors 2Thyroid Carcinoma, Anaplastic 1Pheochromocytoma 1Paraganglioma 1Carcinoid Tumor 1Adenocarcinoma 1

Interventions

Everolimus 19lutetium Lu 177 dotatate 8Octreotide 8lanreotide 7pasireotide 6Temozolomide 6Sunitinib 6pembrolizumab 5gallium Ga 68 dotatate 5Positron Emission Tomography Computed Tomography 5surufatinib 4Sorafenib 4Data Collection 4Carboplatin 43-Iodobenzylguanidine 4Positron-Emission Tomography 3Nivolumab 3Magnetic Resonance Spectroscopy 3Etoposide 3Capecitabine 390Y-octreotide, DOTA-Tyr(3)- 3pentetreotide 2pazopanib 2lenvatinib 2fosbretabulin 2fluorodopa F 18 2cabozantinib 2avelumab 2arginyllysine 2Single Photon Emission Computed Tomography Computed Tomography 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × cabozantinib × NET × Clear all
NCT04400474 2025-06-19

CABATEN

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed
93 enrolled 17 charts
CNSEndocrineHead & NeckNET

Adenocarcinoma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors, Thyroid Carcinoma, Anaplastic

NCT04197310 2025-01-31

Cabozantinib and Nivolumab for Carcinoid Tumors

Dana-Farber Cancer Institute

Phase 2 Completed
19 enrolled 10 charts
EndocrineNET

Carcinoid Tumor, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡